Quintiles Named to FORTUNE Magazine's 2015 List of “World’s Most Admired Companies”
February 19 2015 - 10:31AM
Business Wire
Quintiles, the world’s largest biopharmaceutical services
company, has been named to FORTUNE magazine’s “World’s Most Admired
Companies” list for 2015.
Quintiles CEO Tom Pike (Photo: Business
Wire)
Quintiles is ranked third overall in FORTUNE’s
Healthcare: Pharmacy and Other Services category with
the top ranking for the reputation attribute of “global
competitiveness” and second within the segment for its “people
management.”
FORTUNE's World's Most Admired Companies list is the definitive
report card on corporate reputations. Since 1997, Fortune has
identified, selected and ranked the World’s Most Admired Companies,
uncovering the business practices that make these companies highly
regarded among their peers.
“I would like to congratulate Quintiles’ employees around the
world for making this possible,” said Quintiles Chief Executive
Officer Tom Pike. “Being named one of the World’s Most Admired
Companies is a significant milestone in the history of our
company.
“It is recognition that Quintiles is headed in the right
direction to deliver value for customers as we improve their
probability of success,” Pike continued. “It is now up to all of us
in the organization to live up to these expectations.”
Quintiles recently entered its 33rd year of operation, having
been established at the University of North Carolina at Chapel Hill
in 1982 by biostatistics professors Dr. Dennis Gillings, CBE and
Gary Koch, PhD. The company, which once operated out of a trailer
on the UNC campus, now conducts business in approximately 100
countries.
More than three decades later, Quintiles is the world’s largest
provider of biopharmaceutical development and commercial
outsourcing services as the company helped develop or commercialize
all of 2013’s top-100 best-selling drugs on the market (2014
statistics pending).
During 2014, Quintiles was recognized as the “Best Contract
Research Organization” (CRO) in the UK SCRIP awards, named “Asia
CRO of the Year” by Frost and Sullivan, voted “Best CRO in Asia” in
the BioPharma Asia Industry Awards and was named “Best Contract
Sales Organization (CSO)” in the PharmaField awards as well as
being named to the Fortune 500 for the first time.
Most Admired Methodology
The survey employed by FORTUNE to designate its “World’s Most
Admired Companies” list assesses nine reputation drivers considered
to be crucial to a company’s global success including financial
soundness, long-term investment value, people management, social
responsibility, use of assets, quality of management, quality of
products/services, innovation and global competitiveness.
These attributes were developed prior to the inception of the
Most Admired Companies rankings in the mid-1980s through a series
of interviews with executives and industry analysts to determine
the qualities that make a company worthy of admiration.
Raters are asked to evaluate each eligible company on attributes
by assigning a score from zero ('Poor') to ten ('Excellent'). For
the purposes of the industry rankings, a company’s overall score is
determined through a simple average of the individual attribute
scores. Companies who rank in the top half of their industry are
defined as “most admired” within their industry.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s
largest provider of biopharmaceutical development and commercial
outsourcing services. With a network of more than 32,000 employees
conducting business in approximately 100 countries, we helped
develop or commercialize all of 2013’s top-100 best-selling drugs
on the market. Quintiles applies the breadth and depth of our
service offerings along with extensive therapeutic, scientific and
analytics expertise to help our customers navigate an increasingly
complex healthcare environment as they seek to improve efficiency
and effectiveness in the delivery of better healthcare outcomes. To
learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20150219005907/en/
QuintilesPhil Bridges, Media Relations1-919-998-1653mobile:
1-919-457-6347phil.bridges@quintiles.comorKarl Deonanan, Investor
Relations1-919-998-2789InvestorRelations@quintiles.com
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jul 2023 to Jul 2024